The New Cancer Treatment For Prostate Cancer

The new treatment for prostate cancer has been given an authorization by the Food and Drug Administration of the USA drug regulators have made the decision just recently. The new treatment enables the human in battling prostrate cancer. The medicine is called Provenge which was developed to fight prostate tumor in its later stages.

The new drug costs around ninety three thousand dollars, it very expensive. The dosage intended for every patient must be set in accordance with their needs. The drug has not been considered to take the place of some treatments that are already being used, but can be accessible along with some treatments. Trials have been confirmed that Provenge can give a patient with prostate cancer an extra four months to live while chemotherapy can give only three months in average.

Five hundred twelve men joined in the therapeutic trials intended for the medicine established by Dendreon, a company created in early 90's by Dr. Samuel Strober and also Dr. Edgar Engleman, both of them are Stanford professors. The new treatment persuades the immune system of the body to battle against the tumor. This type of therapy is known as immunotherapy. A comparable treatment for malignancy is assumed to be along the way. Provenge can be most helpful to patients who were effectively treated by the regular forms of therapy.

According to the Chief Executive of The Prostate Cancer Charity, John Neate, treating cancer by means of annoying reactions from the immune system of the body was a clear center of attention of study for several years and it is optimistic to see the theory being interpreted into a new therapy for men. But he gave a warning of the tests ahead in the use of such treatment: "The information that this kind of immunotherapy can offer extra survival advantage is promising. On the other hand, this process of treatment can give multiple challenges. These intricate processes require the removal of the immune cells of the patient from blood circulation and expose them to any protein which is found in most prostate tumors, associated into a resistant stimulating substance".